The forecast puts 2025 sales at $45.8 billion, with Zepbound's $22.9 billion edging past Wegovy's $18.6 billion last year.
Recap by typeshit. Full story at Yahoo Finance.
A short piece on how cravings and snacking urges may change for people taking GLP-1 drugs. Details are thin, so tap through for the full story.
Philstar Life looks at famous names linked to Ozempic for weight loss. Only a search title came through, so details are thin until you open the source.
An international food and agribusiness expert links growing interest in fibre to the spread of GLP-1 drugs. Details are thin beyond the claim itself.
Early trial results suggest the shot could one day help people hold onto weight loss after they come off GLP-1 drugs.
Citing the Wall Street Journal, Daily Mail Australia says personal injury firm Weitz and Luxenberg brought nearly all of the claims against the Wegovy and Ozempic maker.
Local news team runs a verify segment on retatrutide, the experimental weight-loss drug people are buying without approval.
Loading…